Evidence map›Paper›PMID 30226613›Full record

ArticleOncology reports2018

UCA1 overexpression is associated with less aggressive subtypes of bladder cancer.

Laetitia Lebrun, Dina Milowich, Marie Le Mercier, Justine Allard, Yves-Remy Van Eycke, Thierry Roumeguere, Christine Decaestecker, Isabelle Salmon, Sandrine Rorive

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Laetitia LebrunDepartment of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium.
Dina MilowichDepartment of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium.
Marie Le MercierDepartment of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium.
Justine AllardDepartment of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium.
Yves-Remy Van EyckeDIAPath‑Center for Microscopy and Molecular Imaging, ULB, B-6041 Gosselies, Belgium.
Thierry RoumeguereDepartment of Urology, Erasme University Hospital, ULB, B‑1070 Brussels, Belgium.
Christine DecaesteckerDIAPath‑Center for Microscopy and Molecular Imaging, ULB, B-6041 Gosselies, Belgium.
Isabelle SalmonDepartment of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium.
Sandrine RoriveDepartment of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium.
Université Libre de Bruxelles · BEVIB-UAntwerp Center for Molecular Neurology · BEErasmus Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non‑coding RNAs (ncRNAs) have been shown to serve important roles in carcinogenesis via complex mechanisms, including transcriptional and post‑transcriptional regulation, and chromatin interactions. Urothelial carcinoma‑associated 1 (UCA1), a long ncRNA, was recently shown to have tumorigenic properties in urothelial bladder cancer (UBC), as demonstrated by enhanced proliferation, migration, invasion and therapy resistance of UBC cell lines in vitro. These in vitro findings suggested that UCA1 is associated with aggressive tumor behavior and could have prognostic implications in UBC. The aims of the present study were to therefore to investigate the statistical associations between UCA1 RNA expression and UBC pathological features, patient prognosis and p53 and Ki‑67 expression. Chromogenic in situ hybridization and immunohistochemistry were performed on UBC tissue microarrays to characterize UCA1 RNA, and p53 and Ki‑67 expression in 208 UBC cases, including 145 non‑muscle‑invasive and 63 muscle‑invasive cases. UCA1 was observed in the tumor cells of 166/208 (80%) UBC cases tested. No expression was noted in normal stromal and endothelium cells. Patients with UBC that overexpressed UCA1 (35%) had a significantly higher survival rate (P=0.006) compared with that in patients with UBC that did not overexpress UCA1. This prognostic factor was independent of tumor morphology, concomitant carcinoma in situ, tumor grade and tumor stage. In addition, the absence of UCA1 overexpression was significantly associated with a high Ki‑67 proliferative index (P=0.008) and a p53 'mutated' immunoprofile (strong nuclear expression or complete absence of staining; P=0.003). In conclusion, the present results identified UCA1 as potentially being a novel independent prognostic marker in UBC that was associated with a better patient prognosis and that could serve a pivotal role in bladder cancer carcinogenesis.

Indexed as

AdultAgedAged, 80 and overApoptosisBiomarkers, TumorCarcinogenesisCell Line, TumorCell ProliferationDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedRNA, Long NoncodingUrinary Bladder NeoplasmsBiomarkers, TumorRNA, Long NoncodingUCA1 RNA, human

Identifiers

PMID30226613
PMCPMC6151879
OpenAlexW2890393955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.